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Abstract This study aimed to evaluate the experience of
tracheostomy in COVID-19 patients in a Southern Europe
tertiary hospital. Retrospective observational study in tra-
cheostomized patients from April 1, 2020 to February 28,
2021. Data related to tracheostomy were evaluated in
patients with and without COVID-19, including infections
in healthcare professionals involved in patient care. Forty-
two tracheostomies were performed in COVID-19 patients
aged 68.4 ± 11.1 years, predominantly men (71%) and
caucasians (81%). They had at least 1 comorbidity (93%),
on average 3. The most frequent were heart disease (71%),
age[ 65 years (67%) diabetes (40%) and obesity (33%).
The greater number of comorbidities was associated with
the lesser probability of the patient’s recovery (p = .001).
Age (p = .047) and renal failure (p = .013) were associated
with higher mortality. Patients were tracheostomized by
prolonged endo-tracheal intubation (50%), pneumonia
(33%) and extubation failure (10%). Ventilation time
before the tracheostomy (22.9 ± 6.5 days) was higher than
ventilation time after the tracheostomy (7.1 ± 15.1 days)
(p\ 0.001). No differences were found in ventilation time
(p = 0.094) and tracheostomy time (p = 0.514) in the dif-
ferent indications. There were 3 minor complications
(7.1%), 25 discharges (60%) and 11 deaths (26%). During
the same period 49 tracheostomies were performed in
patients without COVID-19, with a homogeneous gender
and age distribution, 31% without comorbidities, with an
average of 1 comorbidity per patient and higher mortality
(43%). Tracheostomy in COVID-19 patients proved to be a
safe procedure for both patients and healthcare profes-
sionals and improves the clinical outcome of patients with
severe infection. The 21-day procedure timing seems
adequate. Comorbidities played an essential role in
patients recovery. Age and renal failure are associated
with a worse vital prognosis.
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Introduction
COVID-19 is the disease caused by the new coronavirus
(SARS-CoV-2), which was first observed in December
2019 in Wuhan, China, and it quickly spread around the
world. Because the virus is highly contagious, the World
Health Organization (WHO) declared COVID-19 a pan-
demic on March 11, 2020. As of February 13, 2021, this
pandemic has resulted in 110,609,979 confirmed cases and
2,452,510 deaths in 215 countries [1].
Epidemiological studies from different countries show
that most infected patients are asymptomatic or have mild
symptoms ([ 80%), while 14% have a serious illness and
need to be hospitalized [2–4]. Among hospitalized patients,
the presence and severity of respiratory failure are usually
the most important causes for intensive care unit (ICU)
admission where patients receive ventilatory support (non-
invasive or invasive ventilation) [4, 5]. Approximately
3–17% of hospitalized patients require invasive mechanical
ventilation [6–9], and about 10% of patients who are
admitted to the ICU will require prolonged intubation for
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more than 14 days [10]. In these cases, tracheostomy has
been considered [2, 4, 5, 11–17].
The ideal time for tracheostomy in patients with
COVID-19 has not been determined. Epidemiological data
on the Portuguese National Health System’s experience on
this matter is also unknown. This represents a considerable
knowledge gap, particularly after January 2021, when
Portugal was the country with the highest number of new
daily cases of SARS-CoV-2 infection per million inhabi-
tants [18].
The aim of this study was to evaluate the experience of
performing a tracheostomy in COVID-19 patients at a
tertiary hospital center in southern Europe. The study
evaluated patients’ characteristics, clinical course, comor-
bidities, outcome, indications, and timing for tra-
cheostomy. It also evaluated data from patients without
COVID-19 who underwent tracheostomy in the same
period. Finally, it checked whether there was a record of
infection in the health professionals who were involved in
these procedures.
Methods
This study was conducted in accordance with the Decla-
ration of Helsinki and was approved by the Ethics Com-
mittee for Health (CES) at the Centro Hospitalar de Lisboa
Ocidental (CHLO) no. 2142/21, Lisbon on May 26, 2021.
Patients were selected from the hospital’s database, and
their records were available through the Information Sys-
tems and Technologies Service (SSTI) at CHLO, EPE. All
patients who underwent tracheostomy at the CHLO from
April 1, 2020 to February 28, 2021 (11 months) were
considered. Patients were admitted to the emergency
department, which, since the beginning of the pandemic
period, has operated under triage criteria that are specific
for COVID-19, as defined by a national health regulation.
Our emergency department provides health care to an
estimated population of 439,944 inhabitants (based on the
2011 census). This is a region on the west coast of Portu-
gal, with a predominantly Caucasian population, in which
access to health care is universal but subject to payment
(moderating fee) for medical care.
The time frame considered for this study was
11 months, from April 1, 2020 to February 28, 2021. The
following data were collected: gender, age, previous
medical history, presenting symptoms, comorbidities, per-
iod under mechanical ventilation, time from intubation to
tracheostomy, time from tracheostomy to decannulation,
complications, mortality, and length of hospital stay.
Ventilator release was defined as the first full 24-h period
without assisted mechanical ventilation. Several comor-
bidities that reflect the most serious findings of the disease
that were reported in the literature have been studied, and
are as follows: heart disease, respiratory disease, age,
diabetes, and renal failure. A body mass index (BMI)
greater than 30 kg/m2, which is defined as obesity by the
WHO, was considered to be a risk factor.
The data were entered into a Microsoft Excel
spreadsheet, and statistical analysis was performed using
the Statistical Package for the Social Sciences (SPSS)
version 26.0 for Microsoft Windows created by IBM,
Illinois, Chicago, USA.
In a first phase, we tested the assumptions for the use of
parametric tests to choose the most appropriate tests. All
data were checked for normal distribution and homogene-
ity, and the appropriate statistical tests were selected based
on the results. The Kendall’s tau-b correlation coefficient
was used to test the correlation between the number of
comorbidities and the outcome (recovered/died), and the
Chi-square test was used to assess the relationship between
each comorbidity and the outcome. The Wilcoxon test was
used to compare mechanical ventilation time before and
after tracheostomy.
To mitigate viral transmission during this aerosol-gen-
erating surgical procedure, tracheostomies were performed
in accordance with the recommendations of the Portuguese
Society of Otorhinolaryngology and Head and Neck Sur-
gery, which included the use of appropriate personal pro-
tective equipment (PPE), minimizing the number of people
present in the operating room, and the use of a negative
room pressure [19]. All tracheostomies were open surgeries
(no cricothyroidotomies were performed) that were per-
formed by 11 surgeons at the two hospitals that comprise
the CHLO. The authors verified if there was any record of
an infection in the health professionals who were involved
in the procedures. Because most of the patients did not
experience viral elimination 21 days after the onset of
symptoms (although viral detection may not truly reflect
the patient’s infectious potential) [11, 12], it was institu-
tionally decided to avoid tracheostomy before 21 days of
endotracheal intubation. This timing was decreased in
cases where intensivists justified that tracheostomies
should be performed earlier for reasons such as the need for
a pulmonary toilet or to reduce and suspend sedation.
Results
From April 1, 2020 to February 28, 2021, 101 tra-
cheostomies were performed, 42 of which in patients with
COVID-19 (Table 1). The patients were predominantly
male (30 patients, 71%), with an average age of
68.4 ± 11.1 years (range between 47 and 90 years).
Thirty-four patients were caucasian (81%), which can be
explained by the demographic composition of the
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institution’s area of influence. Thirty-nine patients (93%)
had at least 1 comorbidity, with an average of 3 comor-
bidities per patient.
The most frequently reported comorbidities were heart
disease (71% of patients), diabetes (40%) and obesity
(33%). Other rare and isolated comorbidities included HIV
infection, low-grade non-Hodgkin’s lymphoma, overlap
syndrome (Sjogren/systemic sclerosis/polychondritis) and
post-kidney transplant status. There was a moderate, pos-
itive and statistically significant correlation between the
number of comorbidities and the outcome (recovery/death)
(rk = 0.44; p = 0.001): the greater the number of comor-
bidities, the lower was the patient likely to recover.
There was a statistically significant relationship between
age comorbidity and the outcome and between renal failure
comorbidity and the outcome. The results show that these
two comorbidities are associated with a higher probability
of death (Table 2). Although heart disease comorbidity was
the most common in patients with tracheostomy, it was not
found to be associated with a worse outcome.
Prolonged orotracheal intubation (OTI) was the most
common indication for tracheostomy (21 patients, 50%),
followed by pneumonia (14 patients, 33%), extubation
failure (4 patients, 10%) and vocal cords paresis (2
patients, 5%) (Table 3).
At the date of the study, 25 patients (60%) had been
discharged and 6 remained hospitalized (Table 4). There
were minor complications related to the procedure in 3
patients (7.1%), which included hemorrhage (2 patients)
and subcutaneous emphysema (1 patient).
The mean time of intubation before the tracheostomy,
defined as the time from the first intubation to the tra-
cheostomy, was 22.9 ± 6.5 days, with a range from 11 to
39 days. The 4 patients who failed extubation required
reintubation before tracheostomy. The mean ventilation
time after tracheostomy was 7.1 ± 15.1, with a range from
0 to 40 days. The average time from tracheostomy to
decannulation was 27.5 ± 19.8 days, with a range from 3
to 99 days. The total time of assisted ventilation was
29.5 ± 11.4 days, with a range from 12 to 68 days.
The ventilation time before the tracheostomy was longer
than the ventilation time after the tracheostomy
(Z = - 5.342; p\ 0.001). No differences were found in
the ventilation time (F = 2,288; p = 0.094) and in the tra-
cheostomy time (F = 0.777; p = 0.514) between the dif-
ferent indications. In these recovered patients,
hospitalization ranged from 27 to 127 days (60.2 ± 31.6).
Table 1 Characteristics of patients with COVID-19 undergoing
tracheostomy
Characteristics n = 42
Age (years) 68.4 ± 11.1
Male (number and %) 30 (71%)
Caucasian (number and %) 34 (81%)
Comorbidities
Heart disease (number and %) 30 (71%)
Age[ 65 years (number and %) 28 (67%)
Diabetes (number and %) 17 (40%)
BMI[ 30 (number and %) 14 (33%)
Renal insufficiency (number and %) 11 (26%)
Chronic respiratory disease (number and %) 9 (21%)
Others (number and %) 5 (12%)
BMI: body mass index
Table 2 Association between the comorbidities of patients with
COVID -19 tracheostomized and the outcome (recovery/death)
Comorbidities Recovery Death v2 p
N % N %
Heart disease 2.771 .096
Yes 20 64.5 10 90.9
No 11 35.5 1 9.1
Chronic respiratory disease 1.974 .160
Yes 5 16.1 4 36.4
No 26 83.9 7 63.6
Age[ 65 years 3.941 .047
Yes 18 58.1 10 90.9
No 13 41.9 1 9.1
BMI[ 30 .062 .804
Yes 10 32.3 4 36.4
No 21 67.7 7 63.6
Diabetes 3.318 .069
Yes 10 32.3 7 63.6
No 21 67.7 4 36.4
Renal insufficiency 6.198 .013
Yes 5 16.1 6 54.5
No 26 83.9 5 45.5
BMI: body mass ı́ndex
Table 3 Indications for tracheostomies in patients with COVID-19
Indications for tracheostomies n = 42
Prolonged OTI (number and %) 21 (50%)
Pneumonia (number and %) 14 (33%)
Extubation failure (number and %) 4 (10%)
Vocal cords paresis (number and %) 2 (5%)
Myopathy (number and %) 1 (2%)
OTI: orotracheal intubation
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In COVID-19 patients who underwent tracheostomy, the
mortality rate was 26% (11 patients). In these patients the
mean oral intubation time before tracheostomy was
25.4 ± 6 days, with a 19 to 35 days variation, the mean
time of hospital stay, in these patients, was 32.6 ± 9.4 with
a 19 to 55 days variation. There was no immediate post-
operative or tracheostomy related deaths. In the patients
that died, the mean time from tracheostomy to death was
7.6 ± 5.3 days with a variation from 2 to 20 days. In the
recovered patients the length of hospital stay was from 27
to 127 days (60.2 ± 31.6).
During the 11 months studied, 49 non-COVID-19 rela-
ted tracheostomies was performed (Table 5). The gender
and age distribution were similar to the COVID-19
patients: 28 were male (57%), 21 female (43%), mean age
65 ± 17.2 years (variation 26 to 95 years), 44 patients
were Caucasian (90%). Fifteen patients (31%) had no
comorbidities, and there was a mean of 1 comorbidity per
patient. Besides advanced age (53% of the patients), the
more frequent were Cardiac illness (29%), Diabetes (24%)
and Obesity (20%).
Non-COVID-19 patients submitted to tracheostomy had
a prolonged hospital stay (69.5 ± 55.1 days), in compare
to the hospital stay in similar patients that didn’t underwent
tracheostomy (neurologic, tumoral, trauma and vascular)
(Table 6). In these patients there was also a high mortality
rate (43%, 21 patients). There were few tracheostomy
related complications (8.1%) that included post-operative
bleeding in 3 patients and cannula exteriorization in 1
patient. Ventilation time form admission to tracheostomy
was shorter than COVID-19 patients (13 ± 8.6 days), due
to a precocious ICU indication, however the time with
tracheostomy was longer (46.5 ± 32.8 days).
In our study there was viral transmission to any of the
involved healthcare professional staff (surgical team or
ward team).
Discussion
This study supports important conclusions about the use of
tracheostomy in patients with COVID-19 because it
included a considerable number of procedures that were
performed since the beginning of the pandemic and for a
considerable period of time, which included a time when
Portugal was the country with the highest number of daily
cases of SARS-CoV-2 infection per million inhabitants.
Table 4 Clinical evolution of COVID-19 tracheostomy patients
Characteristics n = 42
Discharged patients (number and %) 25 (60%)
Admitted (number and %) 6 (14%)
Recovered (n8 e %) 31 (74%)
Total time of assisted ventilation (days) 29.5 ± 11.4 (12–68)
Ventilation to tracheostomy time (days) 22.9 ± 6.5 (11–39)
Ventilation time after tracheostomy (days) 7.1 ± 15.1 (0–40)
Time with tracheostomy (days) 27.5 ± 19.8 (3–99)
Mortality (number and %) 11 (26%)
Ventilation to tracheostomy time (days) 25.4 ± 6 (19–35)
Time with tracheostomy (days) 7.6 ± 5.3 (2–20)
Length of hospital stay (days) 32.6 ± 9.4 (19–55)
Complications (number and %) 3 (7.1%)
Table 5 Characteristics of non-COVID-19 patients submitted to
tracheostomy
Characteristics n = 49
Age (years) 65 ± 17.2
Male (number and %) 28 (57%)
Caucasian race (number and %) 44 (90%)
Comorbidities
Heart disease (number and %) 30 (29%)
Age[ 65 years (number and %) 26 (53%)
Diabetes (number and %) 17 (24%)
BMI[ 30 (number and %) 14 (20%)
Chronic kidney failure (number and %) 3 (6%)
Chronic lung illness (number and %) 5 (10%)
BMI: body mass index
Table 6 Indications and clinical evolution of non-COVID-19 tra-
cheostomy patients
Characteristics n = 49
Indications
Prolonged intubation (number and %) 25 (51%)
Extubation failure (number and %) 7 (15%)
ARDS (number and %) 5 (10%)
Airway tumor (number and %) 5 (10%)
Head trauma (number and %) 3 (6%)
Vocal cord paralysis (number and %) 3 (6%)
Radiotherapy (number and %) 1 (2%)
Ventilation
Total ventilation time (days) 12 ± 19.4
Admission to tracheostomy time (days) 13 ± 8.6
Time with tracheostomy (days) 46.5 ± 32.8
Time of hospital stay (days) 69.5 ± 55.1
Complications (number and %) 4 (8.1%)
Mortality 21 (43%)
ARDS: Acute Respiratory Distress Syndrome
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During the study period, 42 tracheostomies were per-
formed in patients with COVID-19, and 49 tracheostomies
were performed in patients without COVID-19. Thus, the
number of these procedures almost doubled because of the
disease. This necessarily has consequences from an orga-
nizational point of view for otorhinolaryngology services
and for operating theaters and the ICU to ensure that all
patients who are candidates for tracheostomy and who are
referred for the procedure undergo the procedure quickly.
Some comorbidities influence the prognosis of patients
with COVID-19. Our study identified a higher rate of these
comorbidities in patients with COVID-19 (mean of three
comorbidities) compared to patients without COVID (mean
of one comorbidity). The higher number of comorbidities
were found to negatively influence patient recovery, and
older age and renal failure were shown to be associated
with higher mortality in these patients. However, the
mortality of patients who undergo tracheostomy due to a
disease other than COVID-19 was higher because of the
underlying disease (e.g., neurological, trauma, or vascular
reasons).
The advantages for tracheostomy in patients with pro-
longed intubation are the reduction of mechanical venti-
lation time [20], length of ICU stay [21], mortality [22],
risk of developing subglottic stenosis [23], and use of
sedation [21], and there is an improvement in the pul-
monary toilet [24]. COVID-19 patients tend to stay longer
in the ICU, and many of them remain intubated for 1 to
2 weeks or more [2]. The indications for tracheostomy in
COVID-19 patients in our study were similar to those in
non-COVID patients. Many patients do not attempt early
weaning on assisted ventilation (for example, in the first
week), although this does not appear to be a predictive
factor in the inability to wean and extubate. However, some
patients end up needing a tracheostomy (\ 10% of ICU
admissions) [13, 14, 16, 25]. In our study, there was no
higher rate of tracheostomy due to extubation failure in
patients with COVID-19, nor were there any differences in
ventilation and tracheostomy time on the basis of the
indications.
Tracheostomies in patients with COVID-19 were per-
formed 22.9 ± 6.5 days after endotracheal intubation,
which was about 1 week after patients without COVID-19.
The timing of the procedure was influenced by several
factors, including recommendations of some scientific
societies such as the Portuguese Society of Otorhino-
laryngology and Head and Neck Surgery, which argues that
tracheostomy should be performed only when considered
absolutely necessary and as late as possible, ideally in a
period without active infection (21). Tracheostomies that
were performed by otorhinolaryngology were associated
with better survival [17], and the timing of 21 days to
perform the tracheostomy was considered to be adequate
[4, 5, 17, 26].
In non-COVID patients, changes in practice have led
intensivists to indicate tracheostomy on day 7 to 10 after
initial intubation [20] to maximize ICU resource avail-
ability [15, 27]. In COVID-19 patients, although tra-
cheostomy is feasible at the referred timing after initial
intubation [28], it seems advisable to proceed beyond this
period of time due to safety concerns for the healthcare
professionals. The procedure can be considered before
21 days in exceptional situations of prolonged ventilator
dependence, high risk of transmission, poor prognosis for
intubated and ventilated patients [11–13, 29], greater need
for pulmonary toilet, or high sedation levels [24].
In recovered patients, the tracheostomy time (from
procedure to decannulation) was significantly shorter in
patients with COVID-19 (27.5 ± 19.8 days) compared to
patients without COVID-19 (46.5 ± 32.8), which is a
positive indicator of respiratory improvement in patients
with COVID-19.
For the tracheostomies that were performed in both
patients with COVID-19 and patients without COVID-19,
the complication rate was low (7%–8%), and the compli-
cations that were recorded were minor complications. The
surgical teams had the option to perform the tra-
cheostomies in an operating room with all the appropriate
conditions for the positioning, comfort, and safety of
patients and professionals and with the availability of all
the required equipment and devices to perform the proce-
dure and resolve any complications immediately.
Although the risk of coronavirus transmission to
healthcare professionals is high during procedures such as
tracheostomy (after endotracheal intubation, which has a
higher risk, the odds ratio [OR] was 6.6, and for a non-
invasive determination, the OR was 3.1 [30]), in our study,
there was no transmission of the virus to health profes-
sionals. For all teams and all patients, all safety recom-
mendations that were proposed by the authorities and
national and international health societies of scientific
research were followed.
The limitations of this study include the retrospective
collection of medical records, which can affect the accu-
racy of the data. The data were collected by three
researchers to increase its reliability. On the date of data
collection, many patients remained hospitalized, and thus,
results, complications, and mortality may be underreported.
Conclusion
Tracheostomy in COVID-19 patients is indicated in hos-
pitalized patients with severe disease and prolonged oro-
tracheal intubation. The procedure, which is performed
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after day 21 of endotracheal intubation, was shown to be
safe and beneficial. In these patients, there was a mortality
rate of 26%, but the reason for death was not related to the
procedure. There was also a low rate of complications, with
only minor complications occurring in these patients.
The release of assisted ventilation was quick, and there
were no safety problems for the health professionals who
were involved in the procedure. Otorhinolaryngology ser-
vices and operating rooms need to adapt to accommodate a
significantly larger number of tracheostomies that need to
be performed under more demanding safety conditions.
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